APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Proteins and Oral Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Proteins and Oral Vaccines Market Outlook and Growth Opportunities 2026

Report ID 174040790430 December 2025195 pages

Choose your research edition.

Industry ResearchTherapeutic Proteins and Oral Vaccines Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Proteins and Oral Vaccines Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Therapeutic Proteins and Oral Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Proteins and Oral Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Proteins and Oral Vaccines Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Therapeutic Proteins and Oral Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Proteins and Oral Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Proteins and Oral Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Proteins and Oral Vaccines market include Abbott, Sanofi, Merck, Roche, Pfizer, Amgen, TransAlgae, Serum Institute of India and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Therapeutic Proteins and Oral Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Proteins and Oral Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Proteins and Oral Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Therapeutic Proteins and Oral Vaccines market.

Therapeutic Proteins and Oral Vaccines Segment by Company

Abbott

Sanofi

Merck

Roche

Pfizer

Amgen

TransAlgae

Serum Institute of India

Novo Nordisk

MigVax

Lumen Bioscience

Johnson and Johnson

Emergent Biosolutions

Eli Lilly and Company

Biogen

Therapeutic Proteins and Oral Vaccines Segment by Type

Therapeutic Proteins

Oral Vaccines

Therapeutic Proteins and Oral Vaccines Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Therapeutic Proteins and Oral Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Therapeutic Proteins and Oral Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Therapeutic Proteins and Oral Vaccines key companies, revenue, market share, and recent developments.

3. To split the Therapeutic Proteins and Oral Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Therapeutic Proteins and Oral Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Proteins and Oral Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Proteins and Oral Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Proteins and Oral Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Proteins and Oral Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Proteins and Oral Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Proteins and Oral Vaccines industry.

Chapter 3: Detailed analysis of Therapeutic Proteins and Oral Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Therapeutic Proteins and Oral Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Therapeutic Proteins and Oral Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Proteins and Oral Vaccines Industry Trends Table 2. Therapeutic Proteins and Oral Vaccines Industry Drivers Table 3. Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges Table 4. Therapeutic Proteins and Oral Vaccines Industry Restraints Table 5. Global Therapeutic Proteins and Oral Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Proteins and Oral Vaccines Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Proteins and Oral Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Therapeutic Proteins and Oral Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global Therapeutic Proteins and Oral Vaccines Company, Product Type & Application Table 10. Global Therapeutic Proteins and Oral Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Therapeutic Proteins and Oral Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Therapeutic Proteins Table 15. Significant Companies of Oral Vaccines Table 16. Global Therapeutic Proteins and Oral Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Type (2021-2026) Table 20. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharmacies Table 22. Significant Companies of Online Pharmacies Table 23. Significant Companies of Hospital Pharmacies Table 24. Global Therapeutic Proteins and Oral Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Application (2021-2026) Table 28. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Application (2027-2032) Table 29. Global Therapeutic Proteins and Oral Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Region (2021-2026) Table 32. Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Region (2027-2032) Table 34. Global Therapeutic Proteins and Oral Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Therapeutic Proteins and Oral Vaccines Sales Value Market Share by Country (2021-2026) Table 37. Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Therapeutic Proteins and Oral Vaccines Sales Value Market Share by Country (2027-2032) Table 39. Abbott Company Information Table 40. Abbott Business Overview Table 41. Abbott Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio Table 43. Abbott Recent Development Table 44. Sanofi Company Information Table 45. Sanofi Business Overview Table 46. Sanofi Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio Table 48. Sanofi Recent Development Table 49. Merck Company Information Table 50. Merck Business Overview Table 51. Merck Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Merck Therapeutic Proteins and Oral Vaccines Product Portfolio Table 53. Merck Recent Development Table 54. Roche Company Information Table 55. Roche Business Overview Table 56. Roche Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Roche Therapeutic Proteins and Oral Vaccines Product Portfolio Table 58. Roche Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio Table 63. Pfizer Recent Development Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio Table 68. Amgen Recent Development Table 69. TransAlgae Company Information Table 70. TransAlgae Business Overview Table 71. TransAlgae Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio Table 73. TransAlgae Recent Development Table 74. Serum Institute of India Company Information Table 75. Serum Institute of India Business Overview Table 76. Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio Table 78. Serum Institute of India Recent Development Table 79. Novo Nordisk Company Information Table 80. Novo Nordisk Business Overview Table 81. Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio Table 83. Novo Nordisk Recent Development Table 84. MigVax Company Information Table 85. MigVax Business Overview Table 86. MigVax Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio Table 88. MigVax Recent Development Table 89. Lumen Bioscience Company Information Table 90. Lumen Bioscience Business Overview Table 91. Lumen Bioscience Therapeutic Proteins and Oral Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio Table 93. Lumen Bioscience Recent Development Table 94. Johnson and Johnson Company Information Table 95. Johnson and Johnson Business Overview Table 96. Johnson and Johnson Therapeutic Proteins and Oral Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio Table 98. Johnson and Johnson Recent Development Table 99. Emergent Biosolutions Company Information Table 100. Emergent Biosolutions Business Overview Table 101. Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio Table 103. Emergent Biosolutions Recent Development Table 104. Eli Lilly and Company Company Information Table 105. Eli Lilly and Company Business Overview Table 106. Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio Table 108. Eli Lilly and Company Recent Development Table 109. Biogen Company Information Table 110. Biogen Business Overview Table 111. Biogen Therapeutic Proteins and Oral Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio Table 113. Biogen Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Therapeutic Proteins and Oral Vaccines Product Image Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Proteins and Oral Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Proteins and Oral Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Therapeutic Proteins Image Figure 8. Oral Vaccines Image Figure 9. Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Therapeutic Proteins and Oral Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Type (2021-2032) Figure 12. Retail Pharmacies Image Figure 13. Online Pharmacies Image Figure 14. Hospital Pharmacies Image Figure 15. Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Therapeutic Proteins and Oral Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Application (2021-2032) Figure 18. Global Therapeutic Proteins and Oral Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 21. North America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Therapeutic Proteins and Oral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 27. South America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutic Proteins
  • Oral Vaccines
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Sanofi
  • Merck
  • Roche
  • Pfizer
  • Amgen
  • TransAlgae
  • Serum Institute of India
  • Novo Nordisk
  • MigVax
  • Lumen Bioscience
  • Johnson and Johnson
  • Emergent Biosolutions
  • Eli Lilly and Company
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Therapeutic Proteins and Oral Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Therapeutic Proteins and Oral Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Therapeutic Proteins and Oral Vaccines Market Dynamics
  1. 2.1 Therapeutic Proteins and Oral Vaccines Industry Trends
  2. 2.2 Therapeutic Proteins and Oral Vaccines Industry Drivers
  3. 2.3 Therapeutic Proteins and Oral Vaccines Industry Opportunities and Challenges
  4. 2.4 Therapeutic Proteins and Oral Vaccines Industry Restraints
3 Therapeutic Proteins and Oral Vaccines Market by Company
  1. 3.1 Global Therapeutic Proteins and Oral Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Proteins and Oral Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Proteins and Oral Vaccines Company Ranking (2024-2026)
  4. 3.4 Global Therapeutic Proteins and Oral Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global Therapeutic Proteins and Oral Vaccines Company Product Type and Application
  6. 3.6 Global Therapeutic Proteins and Oral Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Therapeutic Proteins and Oral Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Therapeutic Proteins and Oral Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Therapeutic Proteins and Oral Vaccines Market by Type
  1. 4.1 Therapeutic Proteins and Oral Vaccines Type Introduction
  2. 4.1.1 Therapeutic Proteins
  3. 4.1.2 Oral Vaccines
  4. 4.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type
  5. 4.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Type (2021-2032)
  7. 4.2.3 Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Type (2021-2032)
5 Therapeutic Proteins and Oral Vaccines Market by Application
  1. 5.1 Therapeutic Proteins and Oral Vaccines Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application
  6. 5.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Application (2021-2032)
  8. 5.2.3 Global Therapeutic Proteins and Oral Vaccines Sales Value Share by Application (2021-2032)
6 Therapeutic Proteins and Oral Vaccines Regional Value Analysis
  1. 6.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Therapeutic Proteins and Oral Vaccines Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Proteins and Oral Vaccines Country-level Value Analysis
  1. 7.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global Therapeutic Proteins and Oral Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Therapeutic Proteins and Oral Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Therapeutic Proteins and Oral Vaccines Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Therapeutic Proteins and Oral Vaccines Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Therapeutic Proteins and Oral Vaccines Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Therapeutic Proteins and Oral Vaccines Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Therapeutic Proteins and Oral Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Amgen
  32. 8.6.1 Amgen Company Information
  33. 8.6.2 Amgen Business Overview
  34. 8.6.3 Amgen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Amgen Therapeutic Proteins and Oral Vaccines Product Portfolio
  36. 8.6.5 Amgen Recent Developments
  37. 8.7 TransAlgae
  38. 8.7.1 TransAlgae Company Information
  39. 8.7.2 TransAlgae Business Overview
  40. 8.7.3 TransAlgae Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 TransAlgae Therapeutic Proteins and Oral Vaccines Product Portfolio
  42. 8.7.5 TransAlgae Recent Developments
  43. 8.8 Serum Institute of India
  44. 8.8.1 Serum Institute of India Company Information
  45. 8.8.2 Serum Institute of India Business Overview
  46. 8.8.3 Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Product Portfolio
  48. 8.8.5 Serum Institute of India Recent Developments
  49. 8.9 Novo Nordisk
  50. 8.9.1 Novo Nordisk Company Information
  51. 8.9.2 Novo Nordisk Business Overview
  52. 8.9.3 Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Product Portfolio
  54. 8.9.5 Novo Nordisk Recent Developments
  55. 8.10 MigVax
  56. 8.10.1 MigVax Company Information
  57. 8.10.2 MigVax Business Overview
  58. 8.10.3 MigVax Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MigVax Therapeutic Proteins and Oral Vaccines Product Portfolio
  60. 8.10.5 MigVax Recent Developments
  61. 8.11 Lumen Bioscience
  62. 8.11.1 Lumen Bioscience Company Information
  63. 8.11.2 Lumen Bioscience Business Overview
  64. 8.11.3 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Product Portfolio
  66. 8.11.5 Lumen Bioscience Recent Developments
  67. 8.12 Johnson and Johnson
  68. 8.12.1 Johnson and Johnson Company Information
  69. 8.12.2 Johnson and Johnson Business Overview
  70. 8.12.3 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Product Portfolio
  72. 8.12.5 Johnson and Johnson Recent Developments
  73. 8.13 Emergent Biosolutions
  74. 8.13.1 Emergent Biosolutions Company Information
  75. 8.13.2 Emergent Biosolutions Business Overview
  76. 8.13.3 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Product Portfolio
  78. 8.13.5 Emergent Biosolutions Recent Developments
  79. 8.14 Eli Lilly and Company
  80. 8.14.1 Eli Lilly and Company Company Information
  81. 8.14.2 Eli Lilly and Company Business Overview
  82. 8.14.3 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Product Portfolio
  84. 8.14.5 Eli Lilly and Company Recent Developments
  85. 8.15 Biogen
  86. 8.15.1 Biogen Company Information
  87. 8.15.2 Biogen Business Overview
  88. 8.15.3 Biogen Therapeutic Proteins and Oral Vaccines Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Biogen Therapeutic Proteins and Oral Vaccines Product Portfolio
  90. 8.15.5 Biogen Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst